Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

467

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: 0.003% AR-15512 ophthalmic solution
DRUG: AR-15512 vehicle ophthalmic solution

Sponsor

Aerie Pharmaceuticals